Fujirebio said on November 18 that it has earned Japanese regulatory approval for Lumipulse β-Amyloid 1-42-N Plasma, an in vitro diagnostic test that measures the plasma levels of amyloid-beta 1-42 (Aβ42), a biomarker associated with Alzheimer’s disease (AD). The green…
To read the full story
Related Article
- Japan Approves Fujirebio’s Blood-Based pTau217 Test for Alzheimer’s
November 12, 2026
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





